Table 5.
Study Design, Funding, Enrollment, and Key Locations of Current Clinical Trials at Phase I/II for Prostate Cancer, 2022 (as of 5 December 2022).
| No. | NCT Number | Phases | N | Study Type and Design | Completion Date | Collaborators | Locations |
|---|---|---|---|---|---|---|---|
| 1 | NCT03658447 | Phase 1, 2 | 37 | Interventional; Single Group, Open Label, Treatment | Dec-22 | Peter MacCallum Cancer Centre, Australia | Australia |
| 2 | NCT04071236 | Phase 1, 2 | 90 | Interventional; Randomized, Open Label, Treatment | 31-Jan-23 | National Cancer Institute (NCI) | Various, United States |
| 3 | NCT04382898 | Phase 1, 2 | 115 | Interventional; Randomized, Open Label, Treatment | Jul-23 | BioNTech SE | Various, United States, Germany, Hungary, United Kingdom |
| 4 | NCT03689699 | Phase 1, 2 | 60 | Interventional; Randomized, Open Label, Treatment | Aug-23 | Matthew Dallos; Bristol-Myers Squibb; Columbia University | United States |
| 5 | NCT01688492 | Phase 1, 2 | 57 | Interventional; Single Group, Open Label, Treatment | Sep-23 | Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb; Northwestern University; Oregon Health and Science University | United States |
| 6 | NCT03217747 | Phase 1, 2 | 173 | Interventional; Non-Randomized, Open Label, Treatment | 30-Sep-23 | M.D. Anderson Cancer Center; National Cancer Institute (NCI) | United States |
| 7 | NCT02933255 | Phase 1, 2 | 29 | Interventional; Non-Randomized, Open Label, Treatment | 1-Dec-23 | National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC) | United States |
| 8 | NCT03493945 | Phase 1, 2 | 113 | Interventional; Randomized, Open Label, Treatment | 31-Dec-23 | National Cancer Institute (NCI); National Institutes of Health Clinical Center (CC) | United States |
| 9 | NCT05000294 | Phase 1, 2 | 29 | Interventional; Sequential Assignment, Open Label, Treatment | Jun-24 | University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals | United States |
| 10 | NCT03518606 | Phase 1, 2 | 150 | Interventional; Non-Randomized, Open Label, Treatment | 30-Dec-24 | UNICANCER; National Cancer Institute, France; AstraZeneca; Pierre Fabre Laboratories | Various, France |
| 11 | NCT03543189 | Phase 1, 2 | 44 | Interventional; Single Group, Open Label, Treatment | Dec-24 | H. Lee Moffitt Cancer Center and Research Institute; Bristol-Myers Squibb | United States |
| 12 | NCT04109729 | Phase 1, 2 | 36 | Interventional; Single Group, Open Label, Treatment | 30-Apr-25 | University of Utah | United States |
| 13 | NCT05553639 | Phase 1, 2 | 70 | Interventional; Single Group, Open Label, Treatment | Sep-26 | Hookipa Biotech GmbH | United States |
| 14 | NCT04946370 | Phase 1, 2 | 76 | Interventional; Randomized, Open Label, Treatment | Jun-28 | Weill Medical College of Cornell University; United States Department of Defense; Merck Sharp & Dohme LLC | Various, United States |